Avenue Biosciences, a biotechnology company dedicated to accelerating the discovery and development of protein biologics, has announced it has secured $5.7 million in new investment. This funding round marks a significant milestone for the company as it continues its mission to overcome production barriers for life-saving therapies.
Headquartered in San Francisco, USA, with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a proprietary protein engineering platform. This innovative platform integrates organic biology with machine learning to significantly boost protein production. The method is built upon years of scientific research originating from the University of Helsinki, Finland, aiming to provide turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities in biotechnology.
The $5.7 million capital infusion is poised to accelerate Avenue Biosciences' strategic objectives. The company plans to deploy the funds to expand its research and development capabilities, scale its advanced protein engineering platform, and enhance its operational capacity across its global locations. This investment underscores confidence in Avenue Biosciences' approach to addressing critical challenges in biologic drug development.
With this new funding, Avenue Biosciences is well-positioned to drive significant progress in the biotechnology sector. The company anticipates accelerating the realization of new therapeutic possibilities and expanding its impact on the development of life-saving protein biologics, ultimately aiming to ensure no therapy goes unrealized due to production hurdles.
